EMA Authorised: Paxneury (guanfacine hydrochloride) — Neuraxpharm Pharmaceuticals S.L.

View source ↗

Summary

The European Medicines Agency authorised Paxneury, containing guanfacine hydrochloride, by Neuraxpharm Pharmaceuticals S.L. for attention-deficit/hyperactivity …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Paxneury (guanfacine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Attention Deficit Disorder with Hyperactivity. MAH: Neuraxpharm Pharmaceuticals S.L.. Decision date: 26/02/2025